The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Belantamab mafodotin and its place in myeloma treatment
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into the safety and efficacy of belantamab mafodotin for the treatment of multiple myeloma. Dr Cerchione highlights the impressive results observed in many clinical trials evaluating the use of belantamab, including the DREAMM-2 (NCT03525678), DREAMM-7 (NCT04246047), and DREAMM-9 (NCT04091126) trials. Dr Cerchione also highlights the possibility of combining belantamab with other agents in the frontline setting, and the excitement surrounding the use of this agent in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
